Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE-listed (KMB) personal care company with Huggies, Kleenex, Scott, and Cottonelle at $20.1B revenue; competing directly with P&G Pampers and Charmin for global diaper and tissue market leadership.
Kimberly-Clark is a Dallas-based global consumer goods company manufacturing personal care, tissue, and health products under the Huggies (diapers), Kleenex (facial tissues), Scott (paper towels/toilet paper), Cottonelle (bathroom tissue), Pull-Ups (training pants), U by Kotex (feminine care), and Depend (adult incontinence) brand portfolio. Listed on NYSE (NYSE: KMB), Kimberly-Clark was founded in 1872 and generated $20.1 billion in net sales in fiscal year 2024, competing directly with Procter & Gamble (NYSE: PG, Pampers, Bounty, Charmin) in the diaper, tissue, and personal care categories globally.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.